摘要
经选择性支气管动脉灌注(BAI)和经肺动脉药物灌注(PAI)治疗中晚期非小细胞型肺癌10例,共42例次,近期有效率达80%,使5例获得手术治疗机会。全组中位生存期11.5个月。作者对双重动脉药物灌注的机理,疗效进行了分析,指出DAI可以使高浓度化疗药物充分与肺肿瘤细胞接触,发挥最佳疗效。对BAI插管困难或支气管动脉无优势供血的肺肿瘤,可经PAI增强疗效,DAI治疗减少了BAI的次数并可减少由BAI引起的并发症。
AbstractSince the
lung receives blood supply from both the bronchial and pulmonary
arteries,chemotherapeutic agents given through both channels would
give higher local drug concentra-tion and better therapeutic results
in the treatment of lung cancer.In this study,10 patientswith
advanced NSCLC were treated by dual arterial infusion(DAI)of
carboplatin(300mg/m ̄2)and VP-16(200~300mg/m ̄2)twice at 3-week
interval.From DAI treatment,a response rate of 80%(CR 2, PR 6)was
achieved.In 5 patients DAI treatment had madesurgical resection of
the lung cancer possible. The 1-,2-and 3-year survivors were 8,6 and5
respectively,with a median survival time of 11.5 months.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1995年第2期146-148,共3页
Chinese Journal of Oncology